NVCR
NASDAQ HealthcareNovoCure Limited - Ordinary Shares
Medical Devices
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
๐ Market Data
| Price | $16.62 |
|---|---|
| Volume | 3,533,864 |
| Market Cap | 1.92B |
| Beta | 0.820 |
| RSI (14-Day) | 81.7 Overbought |
| 200-Day MA | $12.56 |
| 50-Day MA | $12.23 |
| 52-Week High | $20.06 |
| 52-Week Low | $9.82 |
| Forward P/E | -14.26 |
| Price / Book | 5.49 |
๐ฏ Investment Strategy Scores
NVCR scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (96/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NVCR in your text
Paste any article, transcript, or post โ the tool will extract NVCR and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.